⚠ LIVE — European Consumer Safety Watch 💊 Medicinsk kanal: 18 I løbet af de seneste 7 dage 🍎 Fødevarer: 180 I løbet af de seneste 7 dage 🧸 Kanalens produkter: 48 I løbet af de seneste 7 dage 🟢 Overvågning: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Seneste hentning: for 1 time siden ⚠ LIVE — European Consumer Safety Watch 💊 Medicinsk kanal: 18 I løbet af de seneste 7 dage 🍎 Fødevarer: 180 I løbet af de seneste 7 dage 🧸 Kanalens produkter: 48 I løbet af de seneste 7 dage 🟢 Overvågning: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Seneste hentning: for 1 time siden
🛡️ EUSW
🇩🇰
💊

Trevaclyn

laropiprant;nicotinic acid
Dyslipidæmier
🚫 Tilbagekaldt
Ingen aktive alarmer
Denne medicin har ingen igangværende mangel, sikkerhedsbreve eller tilbagekaldelser.

Hvad det bruges til

Trevaclyn is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of low-density-lipoprotein (LDL) cholesterol and triglycerides and low high-density-lipoprotein (HDL) cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial). Trevaclyn should be used in patients in combination with 3-hydroxy-3-methyl-glutaryl-co-enzyme-A (HMG-CoA)-reductase inhibitors (statins), when the cholesterol-lowering effect of HMG-CoA-reductase-inhibitor monotherapy is inadequate. It can be used as monotherapy only in patients in whom HMG-CoA-reductase inhibitors are considered inappropriate or not tolerated. Diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with Trevaclyn.

⚠️ Patient sikkerhed

No

⚠️ Vi sammenfatter officielle meddelelser. Vi giver ikke lægelig rådgivning. Ved lægelige eller juridiske beslutninger skal du konsultere den relevante myndighed og en kvalificeret fagperson.